Ask AI
Prescribing PrEP in Asia

CME

PrEP to Prevent HIV: Prescribing PrEP in Asia

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: June 09, 2025

Expiration: June 08, 2026

Activity

Progress
1 2
Course Completed

References

  1. World Health Organization. Global HIV Programme. who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis. Accessed May 21, 2025.
  2. Emtricitabine/tenofovir disoproxil fumarate [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2024.
  3. Emtricitabine/tenofovir alafenamide [prescribing information]. Foster City, CA: Gilead Sciences, Inc; 2024.
  4. Cabotegravir extended-release injectable suspension [prescribing information]. Durham, North Carolina: ViiV Healthcare; 2025.
  5. Solomon MM, Lama JR, Glidden DV, et al. Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS. 2014;28:851-859. 
  6. Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;61:572-580.
  7. Glidden DV, Mulligan K, McMahan V, et al. Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine. Clin Infect Dis. 2018;67:411-419. 
  8. Liegeon G, Antoni G, Pialoux G, et al. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis. J Int AIDS Soc. 2020;23:e25420.
  9. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
  10. Fields SD, Tung E. Patient-focused selection of PrEP medication for individuals at risk of HIV: A narrative review. Infect Dis Ther. 2021;10:165-186. 
  11. Ogbuagu O, Ruane PJ, Podzamczer D, et al. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021;8:e397-e407.
  12. Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608. 
  13. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779-1789. 
  14. Brown T, Arao R, Phanuphak N, et al. Bone density changes with CAB-LA or TDF/FTC PrEP in MSM and TGW in HPTN 083. Presented at: the Conference on Retroviruses and Opportunistic Infections 2023. February 19-22, 2023; Abstract 987.
  15. British HIV Association. BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018. bhiva.org/clinical-guideline/PrEP-guidelines/. Accessed May 21, 2025.
  16. ASHM. Australian PrEP guidelines 2024. ashm.org.au/resources/australian-prep-guidelines/. Accessed May 21, 2025.
  17. Centers for Disease Control and Prevention. HIV nexus: CDC resources for clinicians. cdc.gov/hivnexus/hcp/index.html. Accessed May 21, 2025.
  18. World Health Organization. PrEP implementation tool. who.int/tools/prep-implementation-tool. Accessed May 21, 2025.
  19. World Health Organization. Differentiated and simplified pre-exposure prophylaxis for HIV prevention: update to WHO implementation guidance. who.int/publications/i/item/9789240053694. Accessed May 21, 2025.
  20. World Health Organization. HIV drug resistance: brief report 2024. who.int/publications/i/item/9789240086319. Accessed May 21, 2025.
  21. Venter WDF, Fabian J, Feldman C. An overview of tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19:817.
  22. Chan C, Fraser D, Schmidt HMA, et al. PrEP product awareness, preferences, and past experiences among transgender women and men who have sex with men in Asia and Australia: The PrEP APPEAL study. kirby.unsw.edu.au/sites/default/files/documents/PrEP-Preferences-in-Asia-and-Australia-Report-Final_2023_1.pdf
  23. Parikh UM, Mellors JW. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Curr Opin HIV AIDS. 2016;11:49-55.